Home › Funds › ORBIMED ADVISORS LLC › SVA
ORBIMED ADVISORS LLC position in SVA
Sinovac Biotech Ltd.
ORBIMED ADVISORS LLC reported holding 2,718,735 shares of SVA (Sinovac Biotech Ltd.) in its Q2 2026 13F filing — a position valued at US$184.5M, representing 3.71% of its reported portfolio and ranking #5 among its reported holdings. ORBIMED ADVISORS LLC has disclosed SVA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's SVA position evolved
ORBIMED ADVISORS LLC first disclosed a stake in SVA in Q3 2023 at 2,718,735 shares (US$340.0M). Across 12 filings, ORBIMED ADVISORS LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,718,735 shares valued at US$184.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.72M | $340.00M | New |
| Q4 2023 | 2.72M | $340.00M | Hold |
| Q1 2024 | 2.72M | $340.00M | Hold |
| Q2 2024 | 2.72M | $340.00M | Hold |
| Q3 2024 | 2.72M | $340.00M | Hold |
| Q4 2024 | 2.72M | $334.00M | Hold |
| Q1 2025 | 2.72M | $334.00M | Hold |
| Q2 2025 | 2.72M | $334.00M | Hold |
| Q3 2025 | 2.72M | $184.47M | Hold |
| Q4 2025 | 2.72M | $184.47M | Hold |
| Q1 2026 | 2.72M | $184.47M | Hold |
| Q2 2026 | 2.72M | $184.47M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SVA and 13F data
SVA (Sinovac Biotech Ltd.) is a company whose sector is not yet classified in our data. 8 other funds we track also report a position in SVA — the largest reported positions include Vivo Capital, LLC (US$38.2M), Neumann Advisory Hong Kong Ltd (US$2.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SVA
- Vivo Capital, LLC 5.90M sh · $38.19M · Q2 2026
- Neumann Advisory Hong Kong Ltd 315.59K sh · $2.04M · Q3 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held SVA?
ORBIMED ADVISORS LLC has disclosed SVA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in SVA?
As of Q2 2026, ORBIMED ADVISORS LLC holds 2.72M shares of SVA (Sinovac Biotech Ltd.), valued at $184.47M, representing 3.71% of its reported portfolio and ranking #5.
Has ORBIMED ADVISORS LLC been buying or selling SVA?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in SVA.
Which other funds hold SVA?
Other major institutional holders of SVA include Vivo Capital, LLC, Neumann Advisory Hong Kong Ltd, among 8 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.